MediVentures

Managing Director Philipp Große leads the firm. He operates from the Puetter family office's headquarters in Iserlohn, Germany. The governance structure places final investment authority with the family office, aligning fund commitments and co-investments with the broader family capital strategy.

MediVentures is the venture capital arm of the Puetter family office. It was originally structured to make direct early-stage investments in digital health. In 2024, the firm reorganized into a fund-of-funds model, making it operate more like a family-backed institutional LP that also selectively co-invests alongside its partner funds.

Since announcing its 2024 pivot, the primary strategy is fund commitments. The firm enters LP positions of up to €5 million per fund. It retains the capacity to make opportunistic direct co-investments with the funds it has already backed.

The firm focuses on funds active at pre-seed, seed, Series A, and Series B. It also evaluates special vehicles for secondary investments and profit-driven impact funds. This stage coverage runs from company formation through early growth.

The firm's sourcing model relies on relationships with established and first-time GPs across the EU, EFTA, and UK. By entering LP positions, MediVentures gains visibility into the underlying portfolio companies, creating a proprietary pipeline for direct co-investments without maintaining a standalone origination team.

The capital is sourced from the Puetter family, which controls Medice, a German pharmaceutical company headquartered in Iserlohn. The family's industrial wealth in healthcare provides the capital base for MediVentures' venture activities.

The firm's stated areas of interest are digital health, nutrition, clean and reliable energy, environmental and climate tech, ag-tech, and space. It does not mention general enterprise software, fintech, or consumer internet as focus areas, indicating a deliberate exclusion of those sectors from its current mandate.